SelectScience
Join Free
NewsLife Sciences

What next for CRISPR after first therapeutic approvals?

SelectScience

As we celebrate the first regulatory approval of a gene-editing based therapeutic, Casgevy™, for the treatment of sickle cell disease and transfusion-dependent β-thalassemia, we consider the gene-editing challenges that must be overcome before CRISPR gene-editing technology becomes a common treatment modality

12 Feb 2024
Lawrence Howes
Editorial Assistant

Editorial article

Gene-editing techniques possess the unique potential to cure genetic diseases at the molecular level, contrasting with current treatments which tend to rely on alleviating the symptoms of disease. This revolutionary approach offers a one-time, enduring effect instead of a lifelong commitment to managing disease symptoms1. However, challenges of in vivo CRISPR therapeutics currently hinder the potential of CRISPR as a commonplace treatment modality.

With the UK MHRA’s approval of Casgevy (exagamglogene autotemcel - exa-cel) in November 2023, clustered regularly interspaced short palindromic repeat (CRISPR) gene editing has evolved from inception to therapeutic reality in little more than a decade2,3. While this world-first gene therapy treatment represents a significant milestone, we have barely scratched the surface of the potential for gene therapies to revolutionize healthcare.

CRISPR-Cas9 leads the charge

Although the human genome is complex, many common genetic disorders arise from mutations in just a single gene, such as cystic fibrosis, sickle cell disease, Duchenne muscular dystrophy, and Huntington’s disease. There are over 500 monogenic diseases that affect more than 250 million individuals worldwide. DNA sequencing in affected families guides the identification of DNA sequence modifications that could potentially serve as a genetic cure, either by disrupting the function of a harmful or inhibitory gene or by restoring the function of an essential gene4.

This manipulation of the genome is facilitated by gene editing technologies, such as CRISPR and its associated protein (Cas-9). CRIPSPR-Cas9 stands out as the most effective, efficient, and precise method for genome editing when compared to earlier techniques like zinc finger nucleases (ZFN) and transcription activator-like effector nucleases (TALENs)5.

Achieving targeted genomic cleavage relies on two essential components: a homing device and an endonuclease. In the case of CRISPR, a single-stranded RNA (sgRNA) serves as the homing device, guiding the Cas protein (endonuclease) to the intended target site. The recognition process of sgRNA is reliant upon protospacer-adjacent motifs (PAMs), short guanine-enriched sequences at the target site. Cas9's preferred PAM sequence, NGG, is a prevalent motif in the human genome. This facilitates the application of CRISPR technology in medical contexts6.

Casgevy and the code to success

The therapeutic approach of Casgevy involves the use of CRISPR-Cas9 to target the BCL11A gene. This gene functions as a transcription factor that represses expression of the γ-globin gene and hence inhibits the production of fetal hemoglobin in adult erythrocytes. Through precise targeting and the creation of a double-stranded break (DSB) in the BCL11A gene using CRISPR-Cas9 technology, this process facilitates the expression of γ-globin in edited cells through the inactivation of BCL11A7.

To achieve the desired edit in the genomes of a patient’s erythrocytes, autologous hematopoietic stem and progenitor cells (HSPCs) are extracted from the patient’s bone marrow. The HSPCs are genetically edited in vitro via the CRISPR-Cas9 system to reactivate the production of fetal hemoglobin. These cells are then infused back into the patient. The edited HPSCs give rise to fetal hemoglobin producing erythrocytes.

The therapy has been shown to yield clinically meaningful and sustained improvements in hemoglobin levels. This has eliminated the need for transfusion and prevented vaso-occlusive episodes in patients treated with Casgevy, effectively curing patients of the disease at the molecular level8.

The challenges

Casgevy harnessed CRISPR technology to modify patient’s cells in vitro for return to the body. However, this in vitro approach is not applicable to most disease types9.

Stability, efficiency, and safety concerns of the in vivo use of CRISPR-Cas9 technology have hindered its clinical applicability thus far. This includes the potential to induce off-target modifications, stimulate the immune response, and the current lack of an efficient delivery approach10. Solving these challenges of in vivo CRISPR therapeutics is essential to realize the full potential of CRISPR as a commonplace treatment modality.

Immunogenicity

In vivo delivery of CRISPR therapeutics bears immunogenicity challenges as every component has been found to activate the immune system. CRISPR effectors, such as Cas9, can prompt specific effector and memory adaptive immune responses as they are large foreign proteins derived from bacteria or archaea11. Cytotoxicity can result from the secondary structure of gRNAs through its activation of an innate immune response mediated by pattern recognition receptor proteins. Resolving this issue through modification of the gRNA poses a challenge, as the hairpin secondary structures are important to effectively engage Cas proteins and to maintain intracellular stability of the gRNA12. Sadly, a man died in one clinical trial as a result of a strong immune response to a high dose of adeno-associated virus vector. The trial was designed to assess the effectiveness of a CRISPR-Cas9 therapy intended for the treatment of Duchenne muscular dystrophy13.

Off-target modifications

Off-target effects remain a significant hurdle to the safe integration of CRISPR therapeutics into clinical applications. Off-target effects arise when Cas9 acts on non-targeted genomic sites, resulting in cleavages that may lead to unintended and adverse outcomes14. Current computational tools have traditionally shown limited performance in genome-wide off-target prediction, due to lack of comprehensive understanding of the CRISPR molecular mechanism. However, ongoing research is integrating molecular dynamics simulations to enhance the precision of computational analysis, establishing a framework for more accurate genome-wide CRISPR off-target prediction and sgRNA optimization15. Although promising, research indicates that off-target outcomes in therapeutic gene editing are influenced by variations in human genetic diversity. Given the reliance of standard computational tools and biochemical methods on reference genomes, this may suggest that a focus towards variant aware off-target assessment will become crucial to therapeutic genome editing evaluation and offer a powerful approach for comprehensive off-target nomination16.

Stability

In vivo gene therapy products require the use of delivery vectors to prevent immediate degradation and immune clearance. Adeno-associated virus (AAV) vectors are the most commonly used for delivering gene drugs, however, pose limitations for widespread application in disease due to restricted loading capacity, a deficiency in specific targeting ability, and an inability to integrate into the host genome.

Non-viral vectors have been gaining popularity in research in recent years for use in CRISPR therapeutics, including lipid nanoparticles, polymeric nanoparticles, biomimetic nanomaterials, and exosomes. Non-viral vectors with high loading capacities and good safety profiles, like lipid nanoparticles (LNPs), have emerged as excellent choices for delivery, and have been used in clinical trials. However, LNPs frequently elicit immunogenic responses in vivo. On the other hand, exosomes derived from organisms or biofilms prove highly effective in evading immune clearance when utilized as non-viral vector masks. Additionally, the proteins and peptides enriched in the biofilm can facilitate the targeted delivery of gene drugs to specific cells17.

Safety

There have been concerns of the DNA-damage toxicity of CRISPR therapeutics as CRISPR/Cas9 mechanism causes DSBs. This is due to reports of p53 induced apoptosis in response to DSBs introduced by CRISPR. Additionally, on-target large deletions spanning kilobases and complex rearrangements can be unintended consequences, highlighting a significant safety concern for clinical applications18.

Variations of Cas9 which do not induce DSBs have been developed and may provide promise for therapeutic application. For example, dCas9 facilitates transient gene expression manipulation by fusing transcriptional activating or repressing domains or proteins to the DNA-binding effector, avoiding the introduction of DSBs. Cas9 nickase (Cas9n) is another altered Cas9 protein and induces single-stranded breaks rather than DSBs19. These altered Cas9 proteins has given rise to novel and powerful approaches; base editing and prime editing. These approaches accurately incorporate point mutations without the need for DSBs or a DNA donor template20.

References:

 SelectScience. (2023, November 16). Dr. Priya Chockalingam. [online] The Scientists’ Channel®, available at: https://thescientistschannel.com/priya-chockalingam.

 Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A. and Charpentier, E. (2012). A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science, 337(6096), 816–821. https://doi.org/10.1126/science.1225829.

 Medicines and Healthcare products Regulatory Agency. (2023, November 16). MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia. GOV.UK, available at: https://www.gov.uk/government/news/mhra-authorises-world-first-gene-therapy-that-aims-to-cure-sickle-cell-disease-and-transfusion-dependent-thalassemia.

 Doudna, J.A. (2020). The promise and challenge of therapeutic genome editing. Nature, 578(7794), 229–236. https://doi.org/10.1038/s41586-020-1978-5.

 Asmamaw, M. and Zawdie, B. (2021). Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing. Biologics: Targets & Therapy, 15, 353–361. https://doi.org/10.2147/BTT.S326422.

 Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P. and Yu, T. (2023). CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduction and Targeted Therapy, 8(36), 1–23. https://doi.org/10.1038/s41392-023-01309-7.

 Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., Luc, S., Kurita, R., Nakamura, Y., Fujiwara, Y., Maeda, T., Yuan, G.-C., Zhang, F., Orkin, S. H., & Bauer, D. E. (2015). BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature, 527(7577), 192–197. https://doi.org/10.1038/nature15521.

 Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., Ho, T. W., Kattamis, A., Kernytsky, A., Lekstrom-Himes, J., Li, A. M., Locatelli, F., Mapara, M. Y., de Montalembert, M., Rondelli, D., & Sharma, A. (2021). CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. New England Journal of Medicine, 384(3), 252–260. https://doi.org/10.1056/nejmoa2031054.

 Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P., & Yu, T. (2023). CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduction and Targeted Therapy, 8(1), 1–23. https://doi.org/10.1038/s41392-023-01309-7.

 Rasul, M. F., Hussen, B. M., Salihi, A., Ismael, B. S., Jalal, P. J., Zanichelli, A., Jamali, E., Baniahmad, A., Ghafouri-Fard, S., Basiri, A., & Taheri, M. (2022). Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy. Molecular Cancer, 21(1). https://doi.org/10.1186/s12943-021-01487-4.

 Ewaisha, R. and Anderson, K.S. (2023). Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation. Frontiers in Bioengineering and Biotechnology, 11. https://doi.org/10.3389/fbioe.2023.1138596.

 Chew, W. L. (2017). Immunity to CRISPR Cas9 and Cas12a therapeutics. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 10(1), e1408. https://doi.org/10.1002/wsbm.1408.

 Philippidis, A. (2023). Case Study Cites Immune Reaction to High Adeno-Associated Virus Dose in Explaining Duchenne Muscular Dystrophy Trial Death. Human Gene Therapy, 34(13-14), 588–591. https://doi.org/10.1089/hum.2023.29244.bfs.

 Guo, C., Ma, X., Gao, F. and Guo, Y. (2023). Off-target effects in CRISPR/Cas9 gene editing. Frontiers in Bioengineering and Biotechnology, 11:1143157. https://doi.org/10.3389/fbioe.2023.1143157.

 Chen, Q., Chuai, G., Zhang, H., Tang, J., Duan, L., Guan, H., Li, W., Li, W., Wen, J., Zuo, E., Zhang, Q., & Liu, Q. (2023). Genome-wide CRISPR off-target prediction and optimization using RNA-DNA interaction fingerprints. Nature Communications, 14(1), 7521. https://doi.org/10.1038/s41467-023-42695-4.

 Cancellieri, S., Zeng, J., Lin, L. Y., Tognon, M., Nguyen, M. A., Lin, J., Bombieri, N., Maitland, S. A., Ciuculescu, M.-F., Katta, V., Tsai, S. Q., Armant, M., Wolfe, S. A., Giugno, R., Bauer, D. E., & Pinello, L. (2023). Human genetic diversity alters off-target outcomes of therapeutic gene editing. Nature Genetics, 55(1), 34–43. https://doi.org/10.1038/s41588-022-01257-y.

 Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P. and Yu, T. (2023). CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduction and Targeted Therapy, 8(1), 1–23. https://doi.org/10.1038/s41392-023-01309-7.

 Uddin, F., Rudin, C. M., & Sen, T. (2020). CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. Frontiers in Oncology, 10(1387). https://doi.org/10.3389/fonc.2020.01387.

 Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., & Liu, D. R. (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 576(7785), 149–157. https://doi.org/10.1038/s41586-019-1711-4.

 Tao, J., Bauer, D.E. & Chiarle, R. (2023). Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing. Nat Communications, 14, 212. https://doi.org/10.1038/s41467-023-35886-6.

Links

SelectScienceCompany website

Tags

UHPLC and HPLCHigh performance liquid chromatography (HPLC) and ultra high performance liquid chromatography (UHPLC), also known as UPLC, are analytical techniques used to separate, identify and quantitate components of complex mixtures including biological samples such as proteins and lipids as well as chemical mixtures of pesticides, drugs and oils. Both techniques are liquid chromatographic methods but differ by operating pressures (HPLC < 6000 psi < UHPLC ). Components of HPLC and UHPLC systems include columns, detectors, pumps, autosamplers and column heaters. Explore a range of UHPLC and HPLC columns for your specific sample needs including reverse phase, normal phase, ion exchange, HILIC, ion exclusion and size exclusion columns. For more specialized HPLC, explore FPLC, countercurrent LC and simulated moving bed systems. Find the best UHPLC and HPLC equipment in our peer reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Cell / Tissue CultureCell culture or tissue culture is used to study the biology of cells or tissues and to isolate cellular products in an environment which can be manipulated and well defined. Accurately control your culture environment with bioreactors or culture incubators, bind your cells to a surface or together with an extracellular matrix. Distinguish cell types with differential media or proliferate cells with certain characteristics using selective media. Enrich your media with supplements such as growth factors, sera and vitamins. Find the best cell and tissue culture products, kits and equipment in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.ProteomicsProteomics is the systemic bioinformatics study of proteins and amino acids, including their structure, size, function and identification. Tools used in proteomics include chromatography, blotting and gels, protein arrays, mass spectrometry and ELISA and associated analysis software. Analyzers and proteomic systems should be sensitive, high resolution, fast and may be automated for high-throughput.PCR and Thermal CyclingPolymerase chain reaction (PCR) kits and thermal cyclers are used for the in vitro amplification of DNA permitting subsequent analysis and experimental procedures. Explore a range of high-quality polymerase, primers and nucleotides or simplify your workflow with a PCR mastermix. Find reverse transcription PCR (RT-PCR) and cDNA synthesis kits for RNA products and libraries. Quantitatively measure the amplification of DNA with real-time PCR (qPCR) and droplet digital PCR (ddPCR) kits and systems, and discover automated PCR setup solutions to increase throughput. Alternative DNA amplification methods also include recombinase polymerase amplification (RPA) kits. Find the best PCR kits and thermal cyclers and purification equipment in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Cell Lines Stem Cells and Primary CellsPrimary cell cultures, established cell lines and stem cells are vital for <i>in vitro</i> and <i>ex vivo</i> experimentation. High-quality cells, optimized for your applications, alongside optimized cell substrates, growth medium and supplements, are critical for experimental success. Explore a range of cells suitable for your applications, including isogenic cell lines, competent cells, induced pluripotent stem cell (iPSC)-derived cell lines, fungal/bacterial/mammalian cell lines, stem cells and cancer cell lines. Find the best cells for your research in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Flow Cytometry / Cell CountingFlow cytometers are used to count, sort and examine multiple characteristics of cells. Other cell analysis equipment includes image cytometers, cell counters, fluorescence-activated cell sorters (FACS), magnetic-activated cell sorters (MACS), and a range of flow cytometry assay kits. Flow cytometers can reveal information on cell viability, cell proliferation, apoptosis and cell cycle progression, as well as identify cell populations and intracellular or cell-surface molecules. Additionally, some flow cytometers, known as FACS, have an additional sorting function after analysis. Cell counters and image cytometers count live and dead cell populations and can also conduct cell proliferation assays. Find the best flow cytometers, cell counters and cell sorters in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.DNA / RNA Extraction and PurificationPurified DNA and RNA are required for numerous downstream molecular biology applications. Consequently, the importance of high-quality DNA/RNA extraction and purification equipment cannot be underestimated. Many purification kits are available and are typically optimized for nucleic acid type and source, including plasmid DNA, genomic DNA, mRNA, RNA and viral nucleic acid purification kits. Automated extraction and purification of nucleic acids can be implemented with magnetic bead separator instruments or high-throughput purification workstations. Find the best DNA/RNA extraction and purification equipment in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.DNA SequencingDNA sequencing, such as sanger sequencing, is a biological technique that determines the precise order of nucleotide bases in a fragment or template of DNA. DNA sequencers and genetic analyzers are based on capillary electrophoresis, where labeled DNA fragments are electrophoretically separated by size as they migrate through a polymer. Find the best DNA sequencing products, including DNA sequencing kits, genomic libraries and genetic identity kits in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Protein PurificationProtein purification is a vital step in drug discovery, therapeutics, biotech and life science research. The purification process typically involves subcellular or membrane protein extraction with cell lysis kits, separation of proteins from cell debris by filtration or spin columns, and the isolation of proteins of interest from other proteins and impurities with affinity purification (including fusion protein tags and antibody binding proteins A, G and L), immunoprecipitation or chromatographic methods, such as ion exchange, size exclusion and immobilized metal affinity chromatography. All purification methods come in multiple formats for your laboratory needs, including agarose or magnetic beads, resins, columns and filter plates. Find the best protein purification equipment in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Protein CrystallographyProtein crystallization is the process of crystallizing purified proteins for 3D structure analysis by x-ray crystallography. The main methods of protein crystallization include sitting drop, hanging drop and microbatch. It is important to control parameters such as pH, temperature and concentration. Following crystallization, detectors and software are used for data collection and analysis.Gene Expression and Molecular CloningMolecular cloning is a set of techniques that utilizes vectors to transfer recombinant DNA into host cells and is an essential tool for investigating the expression of genes and proteins in bacterial or mammalian cells. A variety of vectors optimized for gene cloning and expression in a range of host organisms are available, alongside competent cells for genetic replication. Here, you can explore a range of molecular tools, high-quality genomic and cDNA libraries, premade clones, transformation and transfection reagents and mutagenesis or gene expression detection assays and expression arrays. Find the best gene expression and molecular cloning products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.In Vivo Imaging Systems<i>In vivo</i> imaging systems, including pre-clinical imaging systems and medical imaging systems are used to non-invasively visualize and capture images of live animals and plants. Monitor the natural processes or diseases of your subjects using small-animal pre-clinical imaging systems, including single photon positron emission tomography (SPECT), positron emission tomography (PET), computed tomography (micro-CT), magnetic resonance imaging (MRI), X-ray radiography, ultrasound, fluorescence and bioluminescence imagers. Multimodal systems and software solutions are also available for correlative analysis of organ, tissue, cell, or molecular-level processes. Find the best in vivo imaging products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Next Generation SequencingNext-generation sequencing (NGS), also known as whole-genome sequencing, high-throughput sequencing and massive parallel sequencing, produces and analyses thousands to millions of nucleotide sequences at once. Sequencing systems operate via varying technologies depending on the manufacturer, including sequencing by synthesis, ligation, pyrosequencing, ion semiconductor and single-molecule real-time sequencing. For NGS, library preparation is paramount to successful sequencing. In this section, explore a range of library preparation kits, from targeted, amplicon-based or hybridization-based kits including epigenomic, transcriptomic and genomic workflows to fragmentation kits. Find the best next-generation sequencing products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Protein QuantificationThe detection and quantification of proteins in a sample is vital across life sciences, pharmaceutical research and clinical diagnostics, and a variety of equipment is available to scientists to simplify the workflow. Proteins of interest can be easily labeled and detected on light-based detection instruments. Immunoassay kits allow you to identify a specific protein of interest and protein detection beads or antibody microarrays allow you to identify multiple specific proteins at once. Protein interactions and enzyme activity can also be monitored with protein-protein interaction assays. Additionally, the biophysical characterization of proteins is made easy with biokinetic analyzers. Find the best protein detection and quantification products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.DNA / RNA QuantificationDetection and quantification of nucleic acids is important in molecular biology, cloning, expression, forensics and clinical diagnostics. Nucleic acids can be detected by labeling with colorimetric, fluorescent or radio labels and using in situ hybridization kits to identify specific sequences. Multiple nucleic acids can be detected and quantified at once using RNA / DNA detection beads or RNA / DNA microarrays. Find the best DNA / RNA Quantification products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.

Related articles

What next for CRISPR after first therapeutic approvals?